Recently, multiple prospective clinical studies have shown that EGFR mutation is a strong predictor of efficacy of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKIs) therapy in advanced NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.